Search

Displaying results 4581 - 4590 of 5449 in total
  1. Drug

    Prostaglandin D2

    go.drugbank.com/drugs/DB02056
    Experimental

    It is released upon activation of mast cells and is also synthesized by alveolar macrophages.

  2. Drug

    5-deoxyflavanone

    go.drugbank.com/drugs/DB03601
    Experimental

    These are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.

  3. Drug

    Rintodestrant

    go.drugbank.com/drugs/DB21472
    Investigational

    Rintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer).

  4. Drug

    Taragarestrant

    go.drugbank.com/drugs/DB21574
    Investigational

    Taragarestrant is under investigation in clinical trial NCT06954961 (A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer).

  5. Drug

    Rimtuzalcap

    go.drugbank.com/drugs/DB16733
    Investigational

    Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.

  6. Drug

    Biricodar

    go.drugbank.com/drugs/DB04851
    Investigational

    The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).

  7. Drug

    Lortalamine

    go.drugbank.com/drugs/DB09187
    Experimental

    This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.

  8. Drug

    Cyanamide

    go.drugbank.com/drugs/DB02679
    Experimental

    It often occurs as the calcium salt, sometimes also referred to as cyanamide. The citrated calcium salt is used in the treatment of alcoholism. [PubChem]

  9. Drug

    Sitimagene ceradenovec

    go.drugbank.com/drugs/DB04907
    Experimental

    It is being developed by Ark Therapeutics.

  10. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.